Captrust Financial Advisors Macrogenics Inc Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $4,184 - $9,442	934 Added 5.99%	16,536 $159,000
Q3 2023 Nov 14, 2023	SELL	$4.48 - $6.19 $2,302 - $3,181	-514 Reduced 3.19%	15,602 $72,000
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $74,455 - $121,514	16,116 New	16,116 $86,000
Q2 2022 Aug 16, 2022	BUY	$2.25 - $9.99 $810 - $3,596	360 Added 321.43%	472 $1,000
Q3 2021 Nov 16, 2021	SELL	$19.74 - $28.7 $671 - $975	-34 Reduced 23.29%	112 $2,000
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $322 - $564	17 Added 13.18%	146 $5,000
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $670 - $3,756	129 New	129 $4,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.